Xopenex hfa and Fenofibrate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Xopenex hfa (levalbuterol tartrate) and Fenofibrate (fenofibrate). Common drug interactions include back disorder among females and migraine among males.

The phase IV clinical study analyzes what interactions people have when they take Xopenex hfa and Fenofibrate. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Xopenex hfa?

Xopenex hfa has active ingredients of levalbuterol tartrate. It is often used in asthma. eHealthMe is studying from 2,529 Xopenex hfa users. Check the latest studies of Xopenex hfa.

What is Fenofibrate?

Fenofibrate has active ingredients of fenofibrate. It is often used in high blood cholesterol. eHealthMe is studying from 40,456 Fenofibrate users. Check the latest studies of Fenofibrate.



On Jul, 06, 2026

30 people who take Xopenex hfa and Fenofibrate together, and have interactions are studied.

Xopenex hfa and Fenofibrate drug interactions.

What are the common drug interactions of Xopenex Hfa and Fenofibrate, by gender? *:

female:

  1. Back disorder
  2. Blood albumin decreased
  3. Blood calcium decreased
  4. Blood chloride increased
  5. Blood creatinine increased
  6. Blood iron decreased
  7. Blood osmolarity increased
  8. Blood potassium decreased
  9. Blood urea increased
  10. Brain natriuretic peptide increased

male:

  1. Migraine (headache)
  2. Anxiety
  3. Groin infection (infection in groin)
  4. Headache (pain in head)
  5. Infusion related reaction
  6. Pain
  7. Renal disorder (kidney disease)
  8. Arthralgia (joint pain)
  9. Back pain
  10. Blood cholesterol decreased

What are the common drug interactions of Xopenex Hfa and Fenofibrate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Hospitalisation

20-29:

n/a

30-39:

n/a

40-49:

  1. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  2. Cardiovascular disorder (heart diseases)

50-59:

  1. Dizziness
  2. Gastritis (inflammation of stomach)
  3. Groin infection (infection in groin)
  4. Headache (pain in head)
  5. Infusion related reaction
  6. Kidney infection
  7. Migraine (headache)
  8. Pain
  9. Pulmonary thrombosis (scarring in the lungs)
  10. Renal disorder (kidney disease)

60+:

  1. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  2. Urinary tract infection
  3. Device related infection
  4. Diabetic neuropathy (neuropathic disorders that are associated with diabetes mellitus)
  5. Escherichia infection (bacterial infection by escherichia coli)
  6. Haemorrhage (bleeding)
  7. Heart rate increased
  8. Malaise (a feeling of general discomfort or uneasiness)
  9. Nephrolithiasis (calculi in the kidneys)
  10. Pollakiuria (abnormally frequent passage of relatively small quantities or urine)

What are the existing conditions these people have? *

  1. Immunodeficiency Common Variable: 9 people, 30.00%
  2. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 5 people, 16.67%
  3. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 13.33%
  4. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 13.33%
  5. Pain: 4 people, 13.33%
  6. Depression: 4 people, 13.33%
  7. Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 4 people, 13.33%
  8. Stress And Anxiety: 3 people, 10.00%
  9. Sleep Disorder: 3 people, 10.00%
  10. High Blood Pressure: 3 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Xopenex hfa and Fenofibrate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Xopenex hfa and Fenofibrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Xopenex hfa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Fenofibrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Xopenex hfa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Fenofibrate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on levalbuterol tartrate and fenofibrate (the active ingredients of Xopenex hfa and Fenofibrate, respectively), and Xopenex hfa and Fenofibrate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: